Windtree Therapeutics, Inc.
WINT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $90 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $17 | $17 | $0 |
| Gross Profit | $0 | -$17 | -$17 | $45 |
| % Margin | – | – | – | 50% |
| R&D Expenses | $1,897 | $2,182 | $2,270 | $2,192 |
| G&A Expenses | $1,855 | $1,802 | $1,820 | $2,229 |
| SG&A Expenses | $1,855 | $1,802 | $1,820 | $2,229 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $16,130 | $0 | $0 | $1,120 |
| Operating Expenses | $19,882 | $3,984 | $4,090 | $5,541 |
| Operating Income | $0 | -$3,984 | -$4,090 | -$5,541 |
| % Margin | – | – | – | -6,156.7% |
| Other Income/Exp. Net | $0 | -$6,647 | $45 | $8,231 |
| Pre-Tax Income | -$31,516 | -$10,631 | -$4,045 | $2,690 |
| Tax Expense | $3,431 | $0 | $0 | -$77 |
| Net Income | -$28,938 | -$10,640 | -$4,045 | $2,767 |
| % Margin | – | – | – | 3,074.4% |
| EPS | -1.08 | -3.06 | -4.63 | 0.27 |
| % Growth | 64.7% | 33.9% | -1,814.8% | – |
| EPS Diluted | -1.08 | -3.06 | -4.63 | 0.27 |
| Weighted Avg Shares Out | 27 | 5 | 11 | 256 |
| Weighted Avg Shares Out Dil | 27 | 5 | 11 | 256 |
| Supplemental Information | – | – | – | – |
| Interest Income | $758 | $198 | $7 | $8 |
| Interest Expense | -$328 | $79 | $20 | $61 |
| Depreciation & Amortization | $0 | $17 | $17 | $18 |
| EBITDA | $0 | -$10,535 | -$4,008 | $2,769 |
| % Margin | – | – | – | 3,076.7% |